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ability to show differences between interventions. The
project investigated the feasibility of deriving relative and
absolute utility values from the RGHQoL. METHODS:
A discrete choice conjoint analysis (CA) task (for elicit-
ing relative utility) and time trade off (TTO) exercise
(absolute utility) were designed using QoL states gener-
ated from a subset of six RGHQoL items. RGH patients
completed tasks via interview. CA data were analysed
using the random effects probit model. For TTO, a
random effects tobit regression was employed to estimate
absolute utility values for combinations of attribute levels
not presented in the valuation exercise. RESULTS: One
hundred and ninety-two interviews were conducted (79
male; 113 female). For CA, all attributes were statistically
signiﬁcantly inﬂuential in determining preferences. An
equation containing preference weights to be applied to
the six RGHQoL items was derived. Inserting values for
relevant levels of each attribute yields an index of relative
utility based on QoL outcomes. Scores generated are
ordinal. A second equation was derived for calculating
absolute utilities using TTO, allowing absolute utility
values to be calculated for each individual. As the TTO
technique possesses cardinal properties, it is possible to
derive QALY scores. CONCLUSIONS: It is feasible to
generate both relative and absolute utility values for
responses to the RGHQoL questionnaire, allowing utility
to be based on true QoL. The formulae derived can be
applied to both existing RGHQoL data and those derived
from future studies.
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OBJECTIVES: To compare and contrast the utilities gen-
erated for quality of life (QoL) states from the recurrent
genital herpes quality of life questionnaire (RGHQoL)
using two main elicitation techniques: conjoint analysis
(CA) and time trade off (TTO). METHODS: A ques-
tionnaire was designed for face-to-face interview 
including QoL states deﬁned by six RGHQoL attributes
representing aspects of QoL. A sample of patients (n =
207) diagnosed with recurrent genital herpes consented
to participate in the study. Interviews were conducted
with 192 (92.8%) of these. Respondents were asked to
compare QoL states using a discrete choice CA frame-
work and to complete a TTO exercise in which they were
asked to indicate how many years spent in speciﬁc QoL
states would be equivalent to 10 years with perfect QoL.
RESULTS: Some degree of concordance was observed
between the CA and TTO elicited utilities. The same
health state achieved the highest utility value regardless
of the elicitation technique used. However, statistical
comparison of CA and TTO elicited values for health
states indicated statistically signiﬁcant differences overall
(Wilcoxon test, p = 0.037). CONCLUSIONS: Unlike CA
elicited utilities, the utilities generated using the TTO
technique are considered to have cardinal properties and
hence have the advantage that they can be used within 
a quality adjusted life year (QALY) framework for eco-
nomic evaluation. However, our results suggest that there
was a much greater degree of intra-respondent variation
in TTO elicited values than CA elicited values. Many
respondents struggled to grasp the concept of TTO and
provided inconsistent responses as a consequence. In con-
trast, the degree of completeness and consistency with 
the discrete choice CA exercise was high. Further research
should explore the potential use of CA in developing 
utilities that possess qualities such that these can be used
directly within a QALY framework.
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OBJECTIVES: Although the antibiotic prescribing rate
for pediatric respiratory tract infections in the ambula-
tory care setting decreased signiﬁcantly from 1989 to
2000, the rate for acute bronchitis remains high. This
study sought to identify factors associated with antibiotic
prescribing for acute bronchitis and to conﬁrm changes
in antibiotic prescribing rates from 1996 to 1999 for
URIs, colds, and bronchitis. METHODS: A retrospective
analysis of antibiotic use in U.S. ofﬁce-based settings 
was conducted using the 1996 and 1999 National 
Ambulatory Medical Care Survey (NAMCS). Children
<18 years diagnosed with acute bronchitis (bronchitis,
ICD-9-CM;466**,490**), nasopharyngitis (common
colds,ICD-9-CM;460**), acute upper respiratory tract
infections (URIs,ICD-9-CM;465**) were selected. We
excluded persons that were diagnosed with any condition
for which an antibiotic may be appropriate. Antibiotic
use was determined by searching all prescription codes
for antimicrobial agents (NDC;0346–0358). Logistic
regression was used to identify signiﬁcant patient, health
system, and physician characteristics associated with
antibiotic prescribing. RESULTS: Over the 1996 to 1999
period, antibiotic prescribing decreased from 73% to
17% and 37% to 20% for colds and URI visits. In 1999,
there were 2.2 million pediatric visits for acute bronchi-
tis and 79.1% received an antibiotic which was relatively
unchanged from the rated of 86% observed in 1996.
Antibiotic classes prescribed for bronchitis included 
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Erythomycins/lincosamind/macrolides (49%), Penicillins
(39%), Cephalosporin (9%) and Sulfonamides/Trimetho-
prim (3%). Out of 6 factors explored, only pediatricians
were more likely to prescribe antibiotics for acute bron-
chitis than non-pediatricians (OR = 12.78; 95% CI,
1.42–115.19). CONCLUSIONS: Our study conﬁrms the
dramatic decrease in potentially inappropriate antibiotic
prescribing for children diagnosed with common colds
and URIs. The rate of potentially inappropriate antibiotic
prescribing remained high (79%) for children diagnosed
with bronchitis with the highest rates observed for chil-
dren seeking care from a pediatrician. More than half of
antibiotic classes prescribed for bronchitis were consid-
ered to be ineffective for underlining pathogens in cases
of bacterial bronchitis complications.
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OBJECTIVES: The objective of this health technology
assessment (HTA) commissioned by the German Agency
for HTA/ German Federal Ministry of Health was to
establish an interdisciplinary expert network, to system-
atically review the evidence on effectiveness and cost-
effectiveness of initial antiviral combination therapy for
chronic hepatitis C (CHC) and to apply these data in the
context of the German health care system. METHODS:
A systematic literature review was conducted and study
quality/transferability to the German context were
assessed using standard instruments of the German
Agency for HTA. A decision-analytic Markov model was
developed including pooled short-term outcomes (sus-
tained virological response [SVR] and respective pooled
relative risks) from a recently published Cochrane
Review, single RCTs, utilities from a large German
quality-of-life survey in CHC patients (n = 428), and
German cost data. The model was used to determine
long-term morbidity, life expectancy, and lifetime costs of
different treatment strategies using the societal perspec-
tive. One- and multi-way sensitivity analyses were per-
formed. RESULTS: International clinical studies indicate
that combination therapy with pegylated interferon and
ribavirin (PCOM) achieves highest SVR (54–61%), fol-
lowed by standard combination therapy with interferon
and ribavirin (SCOM) with 37–54%, and interferon
monotherapy (MONO) with 11–21%. Based on interna-
tional cost-effectiveness studies, SCOM is “cost-effective”
compared to MONO. Our decision analysis conﬁrmed
these ﬁndings for the German health care context. No
published articles were available for assessing the cost-
effectiveness of PCOM. Based on our decision analysis,
PCOM dominated SCOM, and its discounted incremen-
tal cost-effectiveness ratio compared to MONO was
€8,200 per quality-adjusted life year. These results were
robust in sensitivity analyses. CONCLUSIONS: This
HTA suggests that initial combination therapy should
prolong life, improve quality-adjusted life expectancy,
and be cost-effective in patients with chronic hepatitis C.
The combination of pegylated interferon and ribavirin is
currently the most effective and efﬁcient antiviral treat-
ment for CHC.
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OBJECTIVES: High coverage is crucial for the success of
vaccination strategies. We investigate the effect of differ-
ent coverage levels of varicella vaccination in Germany
on the possible elimination of varicella, clinical effective-
ness (measured as percentage of preventable varicella
cases prevented), possibility of age-shifts, and economic
outcomes. METHODS: Using an established, age-
structured, decision-analytic model named EVITA 
(Economic Varicella VaccInation Tool for Analysis), 
we analyze the impact of vaccinating children aged 15
months against varicella-zoster-virus. Main assumptions
are: efﬁcacy 86%, costs discounted by 5%, analytic time
horizon 30 yrs. Coverage levels are varied from 0% to
100%. RESULTS: For coverage levels above 75%, vari-
cella can be eliminated within 26.5 years (at 75%), 18
years (at 85%) and 14.5 years (at 100%). At coverage
levels below 30% clinical effectiveness is smaller than the
respective coverage levels, from 40% to 70% clinical
effectiveness is higher than coverage showing the strong
effect of herd immunity. Above 70% clinical effectiveness
remains nearly constant due to the elimination. Because
vaccination is very effective in reducing the number of
cases in young children, the relative proportion of vari-
cella cases of adolescents and adults increases. However,
the total number of cases declines in all age groups for
coverage levels above 50%, i.e. no age-shift occurs. Costs
rise linear with coverage, savings rise even steeper until
70% coverage and remain constant for higher coverage
levels. Therefore, net savings are greatest at coverage
levels of about 70%. Beneﬁt-cost-ratios rise up to cover-
age levels of 70% and fall for coverage higher than 80%.
All beneﬁt-cost-ratios are above 1 showing that net
savings occur from both perspectives the payers’ and the
societal. CONCLUSIONS: Epidemiological considera-
tions favor coverage levels of more than 75% to elimi-
nate varicella and to ensure that no age-shift occurs. From
